Consider this illustrative case: a 34-week RhD-negative patient presents after a low-speed collision with vaginal bleeding, uterine tenderness, and frequent contractions. A reassuring fetal tracing can tempt the team to treat a Kleihauer-Betke (KB) result as either a rule-out test or a verdict on the whole case. Its main role is narrower: estimate fetomaternal hemorrhage (FMH) to guide Rh immune globulin (RhIG) dosing, especially whether additional doses beyond the standard dose are needed.
The low-speed collision does not make this a clinically minor event once bleeding and uterine symptoms have followed. But neither a positive nor a negative KB result establishes whether placental abruption is present. Keep the assay’s purpose separate from the decisions about maternal stabilization, fetal assessment, and observation.
Use the KB test for dose estimation, not diagnosis
The KB test uses acid elution to identify red blood cells containing fetal hemoglobin in a maternal blood sample. Its result estimates fetal-cell transfer; it does not show where the placenta has separated, measure fetal oxygenation, or tell you whether the fetus is currently well.
| Assessment | What it helps answer | What it does not answer |
|---|---|---|
| KB or another FMH assay | How much fetal-cell exposure may have occurred, to guide RhIG dosing | Whether abruption is present or the fetus is currently stable |
| Fetal heart rate and uterine monitoring | Whether fetal heart-rate changes or uterine activity are evolving | How much fetal blood entered the maternal circulation |
| Ultrasound | Placental location and selected fetal or placental findings | A normal scan does not rule out abruption or quantify FMH |
A negative KB result does not erase the clinical concern raised by bleeding, tenderness, and contractions. A positive result estimates HbF-containing cells in maternal blood and generally supports fetal-cell transfer, but maternal cells containing fetal hemoglobin can complicate interpretation. It is not a diagnosis of abruption and should not, by itself, trigger delivery.
Do not let the test gatekeep prophylaxis
Abdominal trauma and antepartum bleeding are sensitizing events. For an unsensitized RhD-negative patient, arrange event-related RhIG according to the obstetric and blood-bank protocol; the KB result helps guide the dose, not decide whether the event merits prophylaxis. Give RhIG promptly, within the recommended post-event window, rather than waiting for the quantitative result. A recent routine dose at 28 weeks should be documented and discussed with the blood bank; do not assume it settles the dosing plan for a new event.
The history in this case needs one more detail: whether routine RhIG was given at 28 weeks. Obtain or review a current antibody screen before administration when feasible, and tell the blood bank about any previous RhIG dose. Anti-D detected after prophylaxis may be passive; it should not automatically be labeled immune sensitization. Conversely, if the patient has true immune anti-D, RhIG cannot reverse sensitization that has already occurred.
Convert the result carefully
In the United States, a standard 300-microgram RhoGAM dose is labeled to cover up to 15 mL of RhD-positive red blood cells. This is often approximated as about 30 mL of fetal whole blood when a fetal hematocrit near 50% is assumed. The product label expresses coverage in red-cell volume, so check which quantity the laboratory reports.
Do not treat a KB percentage as a vial count. Converting that percentage to an estimated FMH volume depends on the laboratory’s validated method and assumptions; the estimate is not a direct measurement of an exact volume. Use the laboratory’s calculated result and local dosing protocol, and contact transfusion medicine or the blood bank when the result suggests a large hemorrhage, is unexpected, or does not fit the clinical context. An unexpectedly high KB estimate deserves particular care because maternal cells containing fetal hemoglobin can complicate interpretation; an appropriate flow-cytometry method may improve quantification in selected cases.
Let clinical findings—not the KB alone—guide observation
The fetal tracing, contraction pattern, maternal examination, and clinical course remain central to detecting evolving placental or fetal compromise. The 2025 EAST trauma guideline frames KB testing in Rh-negative patients as a way to determine the appropriate RhIG dose; evidence that a positive result predicts adverse pregnancy outcomes is limited. Some local pathways still treat a positive KB as one reason to extend observation, so follow the applicable protocol. In this case, bleeding, uterine tenderness, and frequent contractions already warrant continued obstetric assessment, even if the KB is negative and the first tracing is reassuring.
If maternal status worsens, bleeding continues, contractions intensify, or the fetal tracing becomes abnormal, respond to those findings without waiting for a KB result. Likewise, a large estimated FMH calls for prompt attention to RhIG dosing and specialist input, but does not independently diagnose abruption or determine the timing or route of delivery.
Back to the case
For this patient, draw or review the current antibody screen, confirm her RhD status and prior RhIG history, and arrange event-related prophylaxis according to the obstetric and blood-bank protocol. Use the KB result to check whether additional RhIG is needed. Continue monitoring because of her bleeding, tenderness, and uterine activity—not because the KB can certify that an abruption has or has not occurred. Record the result, the product and dose given, the administration time, and any blood-bank recommendation.
Practical takeaways
- Ask what decision the test informs: KB estimates FMH to guide RhIG dosing.
- Do not use a negative KB to rule out abruption or automatically withhold event-related prophylaxis.
- Do not use a positive KB as an abruption diagnosis or a stand-alone reason to deliver.
- Interpret the reported FMH volume and RhIG dose using the laboratory’s validated method and local protocol.
- In a symptomatic trauma patient, let the fetal tracing, uterine activity, maternal examination, and clinical course guide ongoing assessment.
